Eldorado Hotel & Spa Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2020
Here are the related meetings in 2021:
Antibodies and Vaccines as Drugs for COVID-19 (EK31)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Antibodies as Drugs: From B Cell Biology to New Treatments (B1)
Organizer(s) Paul Carter, Janine Schuurman and Karl Dane Wittrup
February 2—6, 2020
Eldorado Hotel & Spa • Santa Fe, NM USA
Discounted Abstract Deadline: Oct 17, 2019
Abstract Deadline: Nov 5, 2019
Scholarship Deadline: Oct 17, 2019
Discounted Registration Deadline: Dec 5, 2019
Sponsored by BioLegend, Inc., Compass Therapeutics, Incyte Corporation, MorphoSys AG and Surface Oncology
Supported by a grant from Genentech
Supported by a grant from Genentech
Summary of Meeting:
Since the mid-1990s, antibodies have grown steadily into a clinically important pharmaceutical class with over 70 antibody-based drugs approved, predominantly in oncology, autoimmunity and inflammation. As the antibody drug field has expanded and matured in recent years, the field has moved from empirical strategies to deep knowledge-based, designer approaches for which understanding of mechanisms of action is critical; there has also been a trend toward increasingly specialized meetings with a narrow focus such as cancer immunotherapy, bispecifics or B cell biology. In contrast, we are proposing a scientifically diverse program that spans a broad range of different and cutting-edge topics relevant to antibody drug development, including antibodies for infectious disease and antibody pharmacology, topics which are often under-represented at major antibody conferences. Additionally, we have chosen a diverse collection of speakers from junior investigators to seasoned researchers from a wide range of institutions in at least eight different countries. We hope and expect that this approach will stimulate ‘cross-pollination’ between disciplines that span the gamut from basic to translational to clinical sciences with the common theme of antibody drugs for the benefit of patients.
View Scholarships/Awards
Since the mid-1990s, antibodies have grown steadily into a clinically important pharmaceutical class with over 70 antibody-based drugs approved, predominantly in oncology, autoimmunity and inflammation. As the antibody drug field has expanded and matured in recent years, the field has moved from empirical strategies to deep knowledge-based, designer approaches for which understanding of mechanisms of action is critical; there has also been a trend toward increasingly specialized meetings with a narrow focus such as cancer immunotherapy, bispecifics or B cell biology. In contrast, we are proposing a scientifically diverse program that spans a broad range of different and cutting-edge topics relevant to antibody drug development, including antibodies for infectious disease and antibody pharmacology, topics which are often under-represented at major antibody conferences. Additionally, we have chosen a diverse collection of speakers from junior investigators to seasoned researchers from a wide range of institutions in at least eight different countries. We hope and expect that this approach will stimulate ‘cross-pollination’ between disciplines that span the gamut from basic to translational to clinical sciences with the common theme of antibody drugs for the benefit of patients.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, February 2 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 6 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 7 in order to fully experience the meeting.
SUNDAY, FEBRUARY 2
MONDAY, FEBRUARY 3
TUESDAY, FEBRUARY 4
WEDNESDAY, FEBRUARY 5
THURSDAY, FEBRUARY 6
FRIDAY, FEBRUARY 7
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, February 2 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 6 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 7 in order to fully experience the meeting.
SUNDAY, FEBRUARY 2
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
*
Karl Dane Wittrup,
Massachusetts Institute of Technology, USA
Glenn Dranoff,
Novartis Institutes for BioMedical Research, USA
Future Prospects for Cancer Immunotherapy
Future Prospects for Cancer Immunotherapy
09:00—11:15
Immunoglobulin Repertoires: From Basic Biology to Therapeutic Applications
*
Laura M. Walker,
Adimab LLC, USA
Pierre Bruhns,
Institut Pasteur, France
Deep-Mining of Antibody Repertoires for Diagnostics and Therapeutic Antibody Discovery
Deep-Mining of Antibody Repertoires for Diagnostics and Therapeutic Antibody Discovery
Coffee Break
Anupam Singhal,
Berkeley Lights Inc., USA
Short Talk: Reaching the High-Hanging Fruit: Accessing Broad B Cell Diversity to Select Better Lead Candidates in Under 1 Week
Short Talk: Reaching the High-Hanging Fruit: Accessing Broad B Cell Diversity to Select Better Lead Candidates in Under 1 Week
17:00—19:00
Biology of Antibody Generation by B Cells
*
Pierre Bruhns,
Institut Pasteur, France
Facundo D. Batista,
Massachusetts Institute of Technology and Harvard University, USA
B Cell Activation: From Molecular Events to Antibody Production
B Cell Activation: From Molecular Events to Antibody Production
Andrew Bradbury,
Specifica, USA
Drug-Like Antibodies Straight From Selections: Enhanced Affinity & Developability from Specifica’s Generation 3 Platform
Drug-Like Antibodies Straight From Selections: Enhanced Affinity & Developability from Specifica’s Generation 3 Platform
Shane Crotty,
La Jolla Institute for Immunology, USA
Probing the Human Naive B Cell Repertoire, and Developing Immunization Strategies that Enhance Antibody and Germinal Center Responses via Modulation of Immunodominance
Probing the Human Naive B Cell Repertoire, and Developing Immunization Strategies that Enhance Antibody and Germinal Center Responses via Modulation of Immunodominance
Patrick McTamney,
AstraZeneca, USA
Short Talk: Utilizing the Human Body as a Bioreactor: Direct Comparison of in vivo Expressed Biologics (IVEB) Delivery Platforms
Short Talk: Utilizing the Human Body as a Bioreactor: Direct Comparison of in vivo Expressed Biologics (IVEB) Delivery Platforms
08:00—11:00
Advances in Antibodies for Immuno-Oncology
*
Falk Nimmerjahn,
Universitätsklinikum Erlangen, Germany
Teemu T. Junttila,
Genentech, Inc., USA
Optimization of Preclinical Safety and Efficacy of anti-HER2/CD3 TDB
Optimization of Preclinical Safety and Efficacy of anti-HER2/CD3 TDB
Esther Breij,
Genmab, Netherlands
Boosting Anti-Tumor Immunity using Bispecific Antibody Molecules
Boosting Anti-Tumor Immunity using Bispecific Antibody Molecules
Coffee Break
Nicolas Fischer,
Light Chain Bioscience / Novimmune SA, Switzerland
Harnessing Macrophage Activity via Targeted Inhibition of the CD47-SIPRa Axis
Harnessing Macrophage Activity via Targeted Inhibition of the CD47-SIPRa Axis
Jennifer E. O'Neil,
Akrevia Therapeutics, USA
Development of a Highly Potent anti-CTLA-4 Antibody Active Specifically in the Tumor Microenvironment
Development of a Highly Potent anti-CTLA-4 Antibody Active Specifically in the Tumor Microenvironment
Kamal Joshi,
Genentech, Inc., USA
Short Talk: Probing Chain Pairing Preferences in Bispecific Antibodies to Facilitate Production in Single Host Cells
Short Talk: Probing Chain Pairing Preferences in Bispecific Antibodies to Facilitate Production in Single Host Cells
Susumu Uchiyama,
Osaka University, Japan
Short Talk: Hydrogen/Deuterium Exchange Mass Spectrometry Analysis of Therapeutic IgG Molecules
Short Talk: Hydrogen/Deuterium Exchange Mass Spectrometry Analysis of Therapeutic IgG Molecules
14:30—16:30
Career Roundtable
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Paul Carter,
Genentech, Inc., USA
Laura M. Walker,
Adimab LLC, USA
Ning Jenny Jiang,
University of Texas at Austin, USA
Ana Maria Moro,
Instituto Butantan, Brazil
Janine Schuurman,
Genmab B.V., Netherlands
Sanjay Ram,
University of Massachusetts, USA
17:00—19:00
Pharmacology of Antibody Drugs
*
Tomoyuki Igawa,
Chugai Pharmabody Research, Singapore
Amrita Kamath,
Genentech, Inc., USA
PK/PD Considerations for the Development of T-cell Dependent Bispecific Antibodies
PK/PD Considerations for the Development of T-cell Dependent Bispecific Antibodies
Dhaval K. Shah,
University at Buffalo, USA
Tissue Distribution of Antibodies: Pharmacokinetics/Pharmacodynamics Perspective
Tissue Distribution of Antibodies: Pharmacokinetics/Pharmacodynamics Perspective
Tim Paul Hickling,
Pfizer, Inc., USA
Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins
Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins
Rob N. de Jong,
Genmab, Netherlands
Short Talk: Therapeutic IgG Antibody Combinations Acting as Bio-Logic AND Gates
Short Talk: Therapeutic IgG Antibody Combinations Acting as Bio-Logic AND Gates
David P. Humphreys,
UCB Pharma, UK
Short Talk: On Target Hexamerisation of IgG1 Driven by a Mutant Form of IgM tail-Piece C-Terminal Fusion
Short Talk: On Target Hexamerisation of IgG1 Driven by a Mutant Form of IgM tail-Piece C-Terminal Fusion
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Antibody Effector Functions
*
Galit Alter,
MIT and Harvard University, USA
Piet Gros,
Utrecht University, Netherlands
Molecular Mechanisms of Antibody-Mediated Complement Activation
Molecular Mechanisms of Antibody-Mediated Complement Activation
Leo James,
MRC Laboratory of Molecular Biology, UK
Targeted Protein Depletion using Cytosolic Antibodies
Targeted Protein Depletion using Cytosolic Antibodies
Coffee Break
Falk Nimmerjahn,
Universitätsklinikum Erlangen, Germany
The Organ Environment Determines Antibody-Dependent Immunotherapy Responses
The Organ Environment Determines Antibody-Dependent Immunotherapy Responses
Marjolein van Egmond,
VU University Medical Center, Netherlands
IgA as Therapeutic Antibodies 2.0?
IgA as Therapeutic Antibodies 2.0?
Stephanie Langel,
Duke University, USA
Short Talk: Engineering Dimeric IgA Antibodies for Passive Transfer into Breastmilk and Protection against Human Rotavirus in Suckling Neonates
Short Talk: Engineering Dimeric IgA Antibodies for Passive Transfer into Breastmilk and Protection against Human Rotavirus in Suckling Neonates
Irene Nailain Nkumama,
Heidelberg University, Germany
Short Talk: Fc-Dependent Antibody Effector Functions Mediate Protective Immunity against Malaria
Short Talk: Fc-Dependent Antibody Effector Functions Mediate Protective Immunity against Malaria
Yuki Yamaguchi,
Osaka University, Japan
Short Talk: HDX-MS Analysis of IgG-FcRIII Interaction
Short Talk: HDX-MS Analysis of IgG-FcRIII Interaction
17:00—19:00
T Cell Targeting for Cancer Therapy
*
Esther Breij,
Genmab, Netherlands
Thorbald van Hall,
Leiden University Medical Center, Netherlands
CD3-Engagement in the Tumor Microenvironment
CD3-Engagement in the Tumor Microenvironment
Tara Lynn Arvedson,
Amgen Inc., USA
Targeting T Cells to Solid Tumors using BiTE® Molecules
Targeting T Cells to Solid Tumors using BiTE® Molecules
Amir Alpert,
Immatics Biotechnologies, USA
TCR-Based Cancer Immunotherapies to Novel pMHC
TCR-Based Cancer Immunotherapies to Novel pMHC
Ryan Molony,
Novartis Institutes for Biomedical Research, USA
Short Talk: CD8+ T Cells Require CD4+ T Cell Help to Achieve Sustained in vitro Target Tumor Cell Killing Mediated by a CD3-Engaging Bispecific Antibody
Short Talk: CD8+ T Cells Require CD4+ T Cell Help to Achieve Sustained in vitro Target Tumor Cell Killing Mediated by a CD3-Engaging Bispecific Antibody
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Antibodies for the Treatment of Infectious Diseases
*
Sai T. Reddy,
ETH Zurich, Switzerland
Laura M. Walker,
Adimab LLC, USA
Longitudinal Dynamics of the Human B Cell Response to the Yellow Fever 17D Vaccine
Longitudinal Dynamics of the Human B Cell Response to the Yellow Fever 17D Vaccine
Sanjay Ram,
University of Massachusetts, USA
DNA-Encoded Anti-Lipooligosaccharide Monoclonal Antibody Engineered to Enhance Complement Activation as a Vaccination Strategy against Multidrug-Resistant Gonorrhea
DNA-Encoded Anti-Lipooligosaccharide Monoclonal Antibody Engineered to Enhance Complement Activation as a Vaccination Strategy against Multidrug-Resistant Gonorrhea
Coffee Break
Joseph R. Francica,
Vaccine Research Center, National Institutes of Health, USA
A Human Monoclonal Antibody Prevents Malaria Infection by Targeting Sporozoites in the Skin and Liver
A Human Monoclonal Antibody Prevents Malaria Infection by Targeting Sporozoites in the Skin and Liver
Galit Alter,
MIT and Harvard University, USA
A Systems Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity
A Systems Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity
Raymond A. Alvarez,
Ichor Biologics, USA
Short Talk: The Development of Human Monoclonal Antibodies to Treat Andes Hantavirus Infections
Short Talk: The Development of Human Monoclonal Antibodies to Treat Andes Hantavirus Infections
17:00—18:45
Emerging Antibody Drugs for Neurodegenerative, Cardiovascular and Immunological Diseases
*
Marjolein van Egmond,
VU University Medical Center, Netherlands
Tina Schwabe,
Alector, USA
Immune Modulatory Antibody Drugs for Dementia
Immune Modulatory Antibody Drugs for Dementia
Tomoyuki Igawa,
Chugai Pharmabody Research, Singapore
Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors
Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors
Jamie M. Orengo,
Regeneron Pharmaceuticals Inc., USA
Novel Approaches to Treating Allergic Disorders with Monoclonal Antibodies
Novel Approaches to Treating Allergic Disorders with Monoclonal Antibodies
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
